The vast majority of coding variants are rare, and assessment of the contribution of rare variants to complex traits is hampered by low statistical power and limited functional data. Improved methods for predicting the pathogenicity of rare coding variants are needed to facilitate the discovery of disease variants from exome sequencing studies. We developed REVEL (rare exome variant ensemble learner), an ensemble method for predicting the pathogenicity of missense variants on the basis of individual tools: MutPred, FATHMM, VEST, PolyPhen, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP, SiPhy, phyloP, and phastCons. REVEL was trained with recently discovered pathogenic and rare neutral missense variants, excluding those previously used to train its constituent tools. When applied to two independent test sets, REVEL had the best overall performance (p < 10 À12 ) as compared to any individual tool and seven ensemble methods: MetaSVM, MetaLR, KGGSeq, Condel, CADD, DANN, and Eigen. Importantly, REVEL also had the best performance for distinguishing pathogenic from rare neutral variants with allele frequencies <0.5%. The area under the receiver operating characteristic curve (AUC) for REVEL was 0.046-0.182 higher in an independent test set of 935 recent SwissVar disease variants and 123,935 putatively neutral exome sequencing variants and 0.027-0.143 higher in an independent test set of 1,953 pathogenic and 2,406 benign variants recently reported in ClinVar than the AUCs for other ensemble methods. We provide pre-computed REVEL scores for all possible human missense variants to facilitate the identification of pathogenic variants in the sea of rare variants discovered as sequencing studies expand in scale.
Introduction
Interpreting genetic variation from next-generation sequencing (NGS) datasets is essential for the advancement of personalized medicine. 1, 2 The vast majority of variants discovered by NGS are rare. 3, 4 Recent exome and genome sequencing studies have found that roughly 85% of nonsynonymous variants have alternate allele frequencies (AFs) less than 0.5%, and roughly 100-400 rare nonsynonymous variants are discovered per sequenced individual. 3, 4 Rare coding variants play to the missing heritability from genome-wide association studies. 5, 6 However, the majority of nonsynonymous variants discovered by NGS have unknown significance because experimental validation of large numbers of rare variants is infeasible, and association studies require prohibitively large sample sizes to detect rare variants with modest effect sizes with high statistical power. Therefore, computational tools that can accurately predict the pathogenicity of rare variants are needed to help identify those variants that are most likely to cause disease. Many tools for predicting the pathogenicity of missense variants have been developed based on features such as amino acid or nucleotide conservation and biochemical properties of the amino acid substitutions. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] However, individual tools often disagree, in part because they utilize different predictive features. Ensemble methods that combine the results of multiple individual predictors can improve performance. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] However, few existing pathogenicity prediction tools have targeted the interpretation of rare variants. 24 Current tools are often trained on predominantly common neutral variants and some explicitly impose a minimum AF threshold for defining neutral training variants. 15, 21, 25 In contrast, most disease training variants are rare. As a result of this AF imbalance between disease and neutral training variants, tools that rely on AF as a predictive feature might have a lower ability to distinguish disease variants from rare neutral variants than from common ones. 24 Biological differences such as higher conservation scores for rare versus common variants might also make rare neutral variants more difficult to distinguish from disease variants. 24, 29 Despite the fact that the vast majority of nonsynonymous variants discovered by NGS are rare, the performance of existing prediction tools on rare variants is not well known. 30 Thus, there is a growing need for the development and evaluation of tools for predicting the pathogenicity of rare variants.
Here, we present an ensemble method for predicting the pathogenicity of missense variants that outperforms existing approaches overall and when applied to rare variants. The rare exome variant ensemble learner (REVEL) method incorporates recently developed individual prediction tools as features and was trained on recently discovered disease and rare neutral missense variants that did not overlap with the training data for its constituent predictors. We also assembled two large independent test sets of recently discovered pathogenic and benign variants that parallel the likely application of REVEL to newly discovered variants from NGS studies. We benchmark the performance of REVEL and existing ensemble predictors for distinguishing disease mutations from neutral variants across a broad range of AFs. To make our method easily accessible for research and clinical use, we provide pre-computed REVEL scores for all possible human missense variants. 31 
Material and Methods

Random Forest
We trained a random forest on the set of variants described below by using the R ''randomForest'' package 32 with 1,000 binary classification trees. 33, 34 We selected the number of trees to be sufficiently large for the out-of-bag (OOB) error rate to plateau; sensitivity analyses showed that increasing the number of trees to 3,000 did not improve performance on the training dataset. The OOB prediction for a given training variant is the proportion of trees that classified the variant as pathogenic across only those trees in the forest that excluded the variant from their bootstrapped training sample. 33 Four features were selected at random as candidates for each split in the random forest trees, which was the default value for 18 features described below. To address the imbalance in the numbers of available disease and neutral training variants, we sampled the same number (n ¼ 6,182) of disease and neutral variants when generating the bootstrapped training set for each tree in the forest. The importance of each predictive feature was measured by the total decrease in the Gini index 33 (improvement in node purity) for all splits on that feature, averaged over all trees in the forest. and vertebrates). For PolyPhen-2, FATHMM, and PROVEAN, when multiple protein isoforms were associated with a given variant, we used the average score across all isoforms. Missing features were imputed with the k-nearest neighbors method implemented in the R ''impute'' package. 43 Missing feature values for a given variant were assigned the average value of the non-missing values of that feature from its k ¼ 40 nearest neighboring variants; when more than 50% of features were missing for a given variant, we assigned to each missing feature its overall mean across all variants.
Training Variants
Test Sets
We assembled two independent test sets that did not overlap with either the REVEL training data or the training data for the component features of REVEL. 49 University of Chicago Genetic Services Laboratory, Ambry Genetics, and Invitae were downloaded on October 13, 2015. We excluded the following from both test sets 1 and 2: all REVEL training variants, all DM variants added to HGMD prior to August 1, 2012 , and all variants that had previously been used to train individual component features in REVEL. Finally, to eliminate overlap between the two test sets, we excluded any variants that were present in both SwissVar and ClinVar from test set 1 if benign (n ¼ 9) and from test set 2 if pathogenic (n ¼ 12).
Comparators
We compared the performance of REVEL to seven ensemble prediction tools that were recently developed, widely used, and readily implemented: MetaLR, 28 MetaSVM, 28 Eigen, 50 CADD 16 v1.3, DANN, 17 Condel, 19 and KGGSeq 23,24 v0.8. We ran KGGSeq with the default model selection option that chooses an optimized set of features for each variant. 24 We plotted receiver operating characteristic (ROC) curves and compared the area under the ROC curve (AUC) estimates for different tools by using Delong's test 51 implemented in the R ''pROC'' package. 52 We also computed the area under the precision-recall (PR) curve by using the R ''ROCR'' package. 53 For the training variants, REVEL scores were computed by using only the OOB predictions, which have been shown to provide performance estimates that are as accurate as for an independent test set of equal size consisting of variants with similar characteristics. 33 Results
Characterization of REVEL Features
The REVEL ensemble score combines pathogenicity predictions from 18 individual scores (features), including 8 conservation scores and 10 functional scores. Figure 1A shows the correlation among individual features. The conservation scores, as well as LRT and Mutation Taster, were almost all highly (Spearman rank correlation coefficient, R > 0.6) to moderately correlated (0.4 < R < 0.6). Five functional scores (MutationAssessor, PROVEAN, VEST, and PolyPhen-2 HDIV and HVAR) were almost all highly correlated. VEST was also highly correlated with several conservation scores, LRT, and MutationTaster. In contrast, FATHMM had low correlation (R < 0.4) with all other scores, and MutPred and SIFT had low to moderate correlation with other scores. The five most important features in the REVEL random forest were FATHMM, VEST, MutationAssessor, MutPred, and PolyPhen-2 HVAR ( Figure 1B ). The importance measure for an individual feature reflects correlations with other features as well as its intrinsic predictive ability because importance may be shared among correlated features. 34 
Overall Performance of REVEL as Compared with Other Methods
The REVEL ensemble score discriminated well between HGMD disease mutations and putatively neutral ESVs, and an overall AUC of 0.908 was estimated with OOB predictions for the training set ( Figure 2A ). The AUC for REVEL was significantly better than any of its constituent features (maximum p < 10 À12 for any pairwise comparison), among which VEST (AUC ¼ 0.844) and FATHMM (AUC ¼ 0.824) had the highest AUCs (Table S1 ). AUCs for the other individual prediction tools ranged from 0.589 to 0.809 and tended to be higher for functional predictors (0.717-0.844) than for conservation scores (0.589-0.791). The AUC for REVEL was also significantly better than the other ensemble methods (maximum p < 10
À12
for any pairwise comparison), among which MetaLR (AUC ¼ 0.883) and MetaSVM (AUC ¼ 0.879) had the next highest AUCs (Figure 2A ; Table S2 ).
Performance for Rare versus Common Neutral Variants
We next compared the performance of REVEL to that of other ensemble methods for discriminating between HGMD disease mutations, which are predominantly rare, and putatively neutral ESVs with AFs ranging from very rare (0.1%-0.3%) to common (>5%). We found that all of the ensemble methods tended to have a worse ability to discriminate disease mutations from rare neutral variants than from common neutral variants ( Figure 2B ; Table  S2 ). However, compared to other ensemble methods, REVEL had superior discriminatory ability for neutral variants within all AF ranges up to 3%, with the greatest improvements in AUC for rare variants with AF < 0.5% ( Figure 2B ; Table S2 ). For neutral variants with AF > 3%, REVEL had the second highest AUC after MetaLR. In addition, the performance of REVEL appeared to be less sensitive to neutral variant AF than other methods. The AUC range for very rare to common variants was narrowest for REVEL (0.897-0.957) and widest for DANN (0.703-0.897), which appeared to be most sensitive to AF (Table S2 ).
Performance Evaluation in Two Independent Test Sets
In test set 1, consisting of 935 independent disease mutations from SwissVar and 141,051 putatively neutral ESVs, the relative performance of all eight ensemble predictors ( Figure 3 ; Table S3 ) was similar to that observed in the training set. REVEL had the best performance both overall (p < 10 À12 ) and for neutral variants within all AF ranges up to 5%. For common neutral variants with AF > 5%, REVEL was again surpassed only by MetaLR. The improvement in AUC obtained with REVEL versus with the other ensemble methods was again greatest for rare neutral variants. In test set 2, consisting of 1,953 pathogenic and 2,406 benign variants from ClinVar, we confirmed that REVEL had the best performance among the ensemble methods both overall (p < 10 À12 ) and for neutral variants within all AF ranges up to 3% and that the improvement in AUC was greatest for rare neutral variants ( Figure 4 ; Table S4 ). All of the ensemble methods had a better overall ability to distinguish benign versus pathogenic variants from ClinVar than putatively neutral ESVs versus disease variants from SwissVar or HGMD, which could be a consequence of the more stringent definition of benign variants from ClinVar. REVEL also had the best overall performance measured by the area under the PR curve (Table S5 ) across a wide range of proportions of disease variants represented in the training set (4.8%) and test sets 1 (0.7%) and 2 (44.8%).
Interpretation of REVEL Scores
The REVEL score for an individual variant can range from zero to one, reflecting the proportion of trees in the random forest that classified the variant as pathogenic. REVEL score distributions for the 6,182 HGMD disease and 123,706 putatively neutral ESV training variants, and for all 1,125,160 ESVs reported by ESP, ARIC, and KGP, are shown in Figure 5A . The distributions of REVEL scores were very similar for all reported ESVs and the subset of putatively neutral ESV training variants, with only a small shift toward higher scores for all ESVs. Figure 5B shows the percentiles of the REVEL scores separately for disease and neutral training variants or all ESVs. Figure S1 shows the sensitivity and specificity corresponding to different REVEL score thresholds, above which a variant would be classified as pathogenic. 
Discussion
REVEL is an ensemble method for predicting the pathogenicity of rare missense variants. Rare variants are likely to comprise the vast majority of variants of unknown significance discovered in future sequencing studies. We have shown that REVEL consistently has the best overall performance as compared to existing methods, particularly for distinguishing disease mutations from uncommon neutral missense variants with an AF below 3%. To facilitate use by clinicians and researchers, we have pre-computed REVEL scores for all missense variants in dbNSFP v2.7, a database of all potential nonsynonymous single-nucleotide variants in the human genome. REVEL thus addresses the need for a pathogenicity prediction tool with improved accuracy for interpreting rare genetic variants.
The REVEL method has several strengths. First, REVEL was trained and tested on recently identified disease and neutral variants that could closely resemble novel variants discovered by future NGS studies, which are likely to include variants with lower AFs and more modest effects than previously discovered variants. The REVEL neutral training variants were specifically restricted to AFs between 0.1% and 1% to improve performance when interpreting rare variants. Second, REVEL incorporates a larger number of individual predictors than prior ensemble methods, including both MutPred and VEST, which were among the most important features in the REVEL random forest. MutPred scores, in particular, were not previously widely available and have now been computed for all missense variants in dbNSFP v2.7 as part of this study. Finally, we carefully removed from the training and test sets all variants used to train any of the component predictors in REVEL to reduce overfitting and inflated performance estimates.
A key limitation of this study and others is the reliance on pathogenicity assertions from existing databases, which might be inaccurate and incomplete. Misclassification of training and test variants as disease or neutral would limit both the accuracy of the prediction method and the resulting performance estimates. Nonetheless, we expect that the putative disease variants used to train REVEL are enriched for true disease variants as compared to the putative neutral variants, allowing identification of key predictive features of pathogenic variants. An additional complication is that existing pathogenicity assertions for some variants might have been based in part on predictions from popular tools, such as SIFT and PolyPhen-2, potentially resulting in inflated performance of these predictors and ensemble scores that use them. Finally, the performance of REVEL and other ensemble methods is limited by the accuracy of the component predictors and could benefit from inclusion of additional predictors as they become available in the future.
REVEL had the highest overall performance of any method in independent test sets, although its performance on common variants with AFs > 3%-5% was slightly worse than that of MetaLR or MetaSVM. The strong overall performance of REVEL reflects the fact that the majority of neutral variants in the training and test datasets were rare, as expected for novel variants discovered by NGS. Furthermore, although we carefully removed all variants used to train REVEL and its constituent features from the two test sets, we did not systematically exclude training variants for the comparator ensemble scores; thus, the performance estimates for the comparators could be overly optimistic. MetaLR and MetaSVM had the next highest overall performance. These two ensemble methods included many of the same predictive features as REVEL, except for VEST, MutPred, and PROVEAN, and also included the AF, which could contribute to their greater sensitivity to the neutral variant AF. Condel is a weighted average of FATHMM and MutationAssessor, and its lower performance relative to some ensemble methods could be due to the inclusion of fewer predictive features. Eigen employs an unsupervised approach to separate variants into two classes and also uses fewer predictive features than REVEL, MetaLR, and MetaSVM. advantages for genome-wide NGS applications because they provide scores for noncoding and regulatory variants that are on the same scale as for coding variants.
The improved performance of REVEL relative to other ensemble methods was greatest for discriminating between disease and rare neutral variants. This result might be partly explained by the fact that REVEL was trained on rare neutral variants with AF < 1% and did not rely on AF as a predictive feature. To our knowledge, one other ensemble predictor, KGGSeq, 24 was similarly trained on rare neutral variants. KGGSeq uses many of the same component predictors as REVEL, except for MutPred, and also includes CADD as a predictive feature. However, KGGSeq adaptively selects an optimal subset of features rather than using all features to predict the pathogenicity of each variant, in part to allow exclusion of features with missing data. Possible explanations for the improved performance of REVEL over KGGSeq include use of all features for all variants by first imputing missing scores, importance of MutPred as a predictive feature, and use of a random forest approach rather than logistic regression. REVEL also outperformed its individual constituent prediction tools, as expected for ensemble methods. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The top-performing individual tools on our training dataset were VEST, 15 FATHMM, 14 and MutPred, 8 consistent with their high importance in the REVEL random forest. VEST predictions are based on a particularly large set of 86 basic genomic and protein annotations and had the best performance among the individual tools. FATHMM uses a hidden Markov modeling approach to analyze multiple sequence alignments and alignments of conserved protein domain families to compute position-specific amino acid probabilities. The uniqueness of this method might contribute to the low correlation between FATHMM and other prediction tools and high importance in REVEL. 28 Finally, the strong performance of MutPred could be because its predictions are based on a particularly detailed model of protein structural and functional properties, including secondary structure, solvent accessibility, functional domains, methylation, phosphorylation, and glycosylation, with quantitative estimates of the probability of losing each property as a result of a particular amino acid change.
In conclusion, REVEL is an ensemble method that outperforms existing tools for distinguishing disease variants from rare neutral variants. REVEL can be used to prioritize the most likely clinically or functionally relevant variants among the sea of rare variants that are increasingly discovered as sequencing studies expand in scale. For example, REVEL scores have been used by the International Consortium of Prostate Cancer Genetics as weights for combining variants discovered by exome sequencing in gene-level case-control studies. Pre-computed REVEL pathogenicity scores for all possible human missense variants, based on GENCODE v9 gene annotations 54 for hg19, are available for download (see Web Resources). To aid interpretation, we also provide estimates of REVEL sensitivity and specificity for different score thresholds and the quantiles of the REVEL score in over one million ESVs observed in KGP, ESP, and ARIC. Future studies might explore the application of REVEL to specific genes to evaluate its clinical utility for interpreting variants of unknown significance for a broad spectrum of clinical conditions. 
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